Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07345975

Characterization of Opposition to Organ Donation at Strasbourg University Hospital in 2024-2025

In 2024, 29,000 people are waiting for organ transplants in France, and only 6,034 transplants were performed during the year. 852 people died while waiting for a transplant. The gap between the number of available transplants and the number of patients waiting for transplants has been widening since the 1990s; there is talk of a shortage of transplants. There is therefore an urgent need to find more transplants and mobilize the entire population to this end.

French law supports presumed consent, meaning that we are all donors unless we have expressed otherwise during our lifetime. In fact, 80% of French people say they are in favor of organ donation after their death, but few discuss it with their loved ones. When families are approached about multi-organ removal to gather any opposition from the deceased, the refusal rate is 37% (compared to an expected 20%).

It is difficult to determine whether this opposition truly comes from the deceased themselves, their loved ones, uncertainty, or the situation. As this is the leading cause of non-donation, it is essential to better characterize this opposition in order to reduce it and allow for more organ donation and, ultimately, transplantation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service d'Anesthésie, Réanimation et Médecine Périopératoire - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Charlotte POUSSARDIN, MD

CONTACT

[email protected]

33 3.69.55.16.21

Charlotte POUSSARDIN, MD

PRINCIPAL_INVESTIGATOR

Sarah BOCQUILLON, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are brain dead and/or eligible for a Maastricht 3 protocol (discontinuation of active treatment with death due to circulatory arrest in intensive care)
  • Hospitalized in the intensive care unit of the Strasbourg University Hospital or transferable to the Strasbourg University Hospital for multi-organ removal (anticipated approach)
  • Existence of relatives with whom discussion is possible
  • Presence of organ procurement coordination at the initial donation interview

Exclusion criteria

  • Absence of relatives of the deceased (no interview with them)
  • Absence of organ procurement coordination during the initial discussion with relatives regarding organ and tissue procurement

Treatment and study plan

Primary outcomes

  1. Distribution of positions regarding organ donation (certain, uncertain, unknown)

    Time frame: Up to 12 months

    Distribution of positions regarding organ donation (certain, uncertain, unknown):

    For illustration purposes:

    • Certain position: ≈ 65%
    • Favorable: ≈ 55%
    • Opposed: ≈ 10%
    • Uncertain position: ≈ 25%
    • Unknown/unexpressed position: ≈ 10%

Study contacts

Contact information is provided by the study sponsor or research team.

Charlotte POUSSARDIN, MD

CONTACT

[email protected]

33 3.69.55.16.21

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: OPPO-PMO

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jan 16, 2026
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.